The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.
 
Rashmi Khanal
No Relationships to Disclose
 
Amitkumar Mehta
Stock and Other Ownership Interests - WITTY HEALTH
Consulting or Advisory Role - AstraZeneca; BeiGene; Gilead Sciences; Incyte; Incyte; Kyowa Kirin International; Novartis; Pharmacyclics; Roche/Genentech; Seagen; TG Therapeutics
Speakers' Bureau - Adaptive Biotechnologies; BeiGene; Epizyme; Gilead Sciences; Incyte; Kite, a Gilead company; Kyowa Kirin International; Seagen
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Aileron Therapeutics (Inst); Artiva (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Forty Seven (Inst); Gilead Sciences (Inst); I-Mab (Inst); incyte (Inst); Innate Pharma (Inst); Juno Therapeutics (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Pharmacyclics/Janssen (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Joseph J. Maly
No Relationships to Disclose
 
Houston Holmes
Leadership - Exuma Biotech
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene/Juno; Celgene; crispr therapeutics; Epizyme; Genentech; Janssen; Karyopharm Therapeutics; Kite/Gilead; Rigel; TG Therapeutics
Speakers' Bureau - Dova Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Seagen
Research Funding - ADC Therapeutics (Inst); Adicet Bio (Inst); Allogene Therapeutics (Inst); Artiva (Inst); Autolus (Inst); Bristol-Myers Squibb/Celgene (Inst); Caribou Biosciences (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Precision Biosciences (Inst); Viracta Therapeutics (Inst)
 
Jennifer N. Saultz
Research Funding - Ikena Oncology
 
Ayad Hamdan
No Relationships to Disclose
 
Anne M. Robinson
Employment - Artiva
Stock and Other Ownership Interests - Artiva
Consulting or Advisory Role - Artiva
Travel, Accommodations, Expenses - Artiva; Artiva
 
Mili Mandal
Employment - Artiva
Stock and Other Ownership Interests - Artiva; Fate Therapeutics; Kinnate Biopharma (I)
Patents, Royalties, Other Intellectual Property - Artiva; Bristol-Myers Squibb (I); Fate Therapeutics; GlaxoSmithKline; Kinnate Biopharma (I)
 
Aakash Patel
Employment - Artiva; Merck
Travel, Accommodations, Expenses - Artiva
 
Thorsten Graef
Employment - Abbvie; Artiva
Leadership - Artiva
Stock and Other Ownership Interests - Abbvie; Artiva; Johnson & Johnson
 
Anita G. Seto
Employment - Artiva
Stock and Other Ownership Interests - Artiva; Expansion Therapeutics; Viridian Therapeutics
Travel, Accommodations, Expenses - Artiva
 
Umar Farooq
Honoraria - Caribou Biosciences; Kite, a Gilead company; Morphosys
Research Funding - Checkmate Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company